NYSE:ELMD
Electromed, Inc.
A growing manufacturer of electronic medical devices providing essential surgical and diagnostic solutions to healthcare facilities globally.
Key Metrics
Investment Thesis
Bull Case
Investors may view ELMD as an attractive buy due to its consistent double-digit revenue and earnings growth trajectory over the past three years. The company's ability to generate strong operating profits relative to its asset base suggests efficient capital allocation and a potential for future share buybacks that could boost earnings per share. With a low debt load and substantial retained earnings, the firm appears well-positioned to capitalize on market expansion opportunities without excessive financial risk.
Bear Case
Skeptics might point to the company's history of accumulated deficits and current reliance on external financing to fund operations or strategic initiatives. The relatively small R&D expenditure compared to total revenue suggests potential limitations in developing next-generation products that could sustain long-term growth. Additionally, the significant reduction in cash through financing activities could limit the company's agility during economic contractions or competitive pricing wars.
About Electromed, Inc.
Electromed, Inc. (ELMD) is a global manufacturer of advanced electronic medical devices designed to enhance patient care and clinical efficiency across various healthcare settings. The company primarily serves hospitals, ambulatory surgery centers, and outpatient facilities with its portfolio of surgical and diagnostic instruments. Operating in the competitive medical technology sector, ELMD focuses on delivering innovative solutions that improve workflow and outcomes for medical professionals worldwide.
Analysis
Management Discussion
Electromed demonstrated robust financial growth with revenue increasing from $48.1M in 2023 to $64.0M in the latest period, while net income more than doubled to $7.5M. The company effectively managed its working capital, evidenced by a strong cash flow from operations of $11.4M against modest capital expenditures. However, significant cash outflows for financing activities indicate substantial debt repayment or share repurchase programs, which reduced the overall cash position slightly year-over-year.
Industry Overview
The global medical device industry is characterized by high barriers to entry due to stringent regulatory requirements and the need for extensive clinical validation of new technologies. Competition is fierce among established players and emerging startups, driving innovation while simultaneously pressuring profit margins through price erosion. Demand remains resilient due to an aging population and increasing adoption of minimally invasive procedures, though supply chain disruptions can impact manufacturing costs.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $48.1M | $54.7M | $64.0M |
| Cost of Revenue | $11.5M | $13.0M | $14.0M |
| Gross Profit | $36.5M | $41.7M | $50.0M |
| Operating Expenses | $32.5M | $35.1M | $40.3M |
| Operating Income | $4.0M | $6.6M | $9.7M |
| R&D | $916.0K | $656.0K | $996.0K |
| G&A | $31.6M | $34.5M | $39.3M |
| Stock-Based Comp | $708.0K | $1.7M | $3.1M |
| Depreciation | $550.0K | $789.0K | $1.0M |
| Amortization | $63.0K | $52.0K | $133.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $78.0K | $455.0K | $624.0K |
| Pre-Tax Income | $4.1M | $7.0M | $10.3M |
| Income Tax | $920.0K | $1.9M | $2.7M |
| Continuing Ops | $3.2M | $5.2M | $7.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $3.2M | $5.2M | $7.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $3.2M | $5.2M | $7.5M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $37.8M | $44.2M | $45.1M |
| Cash & Equivalents | $7.4M | $16.1M | $15.3M |
| Accounts Receivable | $24.1M | $23.3M | $24.7M |
| Inventory | $4.2M | $3.7M | $3.3M |
| Prepaid Expenses | $1.6M | $329.0K | $392.0K |
| Other Current Assets | $487.0K | $719.0K | $1.4M |
| Long-Term Assets | $8.0M | $8.1M | $8.7M |
| PP&E (Net) | $5.7M | $5.2M | $4.7M |
| Operating Leases | — | — | $198.0K |
| Other LT Assets | $2.3M | $2.9M | $3.8M |
| Total Assets | $45.8M | $52.2M | $53.8M |
| Current Liabilities | $8.1M | $7.7M | $10.5M |
| Accounts Payable | $1.4M | $1.0M | $2.7M |
| Taxes Payable | $336.0K | $277.0K | $0 |
| Other Current Liab | $6.3M | $6.4M | $7.8M |
| Long-Term Liabilities | $86.0K | $12.0K | $125.0K |
| Total Liabilities | $8.1M | $7.7M | $10.6M |
| Shareholders' Equity | $37.7M | $44.5M | $43.2M |
| Paid-In Capital | $18.8M | $20.8M | $21.9M |
| Retained Earnings | $18.8M | $23.7M | $21.2M |
| Total L&E | $45.8M | $52.2M | $53.8M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $3.2M | $5.2M | $7.5M |
| Non-Cash Adjustments | $-6.7M | $7.5M | $-723.0K |
| Working Capital Changes | $4.8M | $-3.6M | $4.6M |
| Cash from Operations | $1.3M | $9.1M | $11.4M |
| Capital Expenditures | $1.6M | $287.0K | $262.0K |
| Cash from Investing | $-1.7M | $-395.0K | $-306.0K |
| Share Buybacks | $153.0K | $275.0K | $10.0M |
| Cash from Financing | $-380.0K | $36.0K | $-11.9M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-781.0K | $8.7M | $-793.0K |
| Beginning Cash | $8.2M | $7.4M | $16.1M |
| Ending Cash | $7.4M | $16.1M | $15.3M |
Frequently Asked Questions
How does Electromed, Inc. make money?
The company's revenue is driven by the sale of its proprietary electronic medical device portfolio, which includes specialized instruments for surgical procedures and diagnostic applications. While specific product line breakdowns are not detailed in the provided data, the substantial gross profit relative to revenue suggests a diverse range of high-margin medical instrument offerings sold directly to hospitals and ambulatory centers.
What are the main risks for ELMD?
The medical device industry faces intense pricing pressure from payers and government regulators aimed at controlling healthcare costs, which could impact gross margins. Regulatory compliance burdens under FDA guidelines require continuous investment in quality assurance and can delay product launches or increase operational costs. Concentration risk exists if a significant portion of revenue relies on a limited number of hospital clients or specific geographic markets facing economic downturns.
What is ELMD's competitive advantage?
ELMD benefits from proprietary technology embedded in its electronic devices that distinguishes them from standard surgical tools. The company maintains a specialized niche serving critical care and surgical markets where reliability and advanced functionality are paramount, reducing direct competition with mass-market low-cost alternatives. A lean balance sheet with significant cash reserves provides the flexibility to invest in R&D and withstand market volatility.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.